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Teriflunomide treatment reduces B cells in
patients with MS
ABSTRACT
Objective: To study the immunomodulatory effect of teriflunomide on innate and adaptive immune
cell populations through a pilot, open-label, observational study in a cohort of patients with
relapsing-remitting MS.
Methods: Blood lymphocytes were isolated from 10 patients with MS before and after 3 or 12
months of treatment. Adaptive and innate immune cell subsets were analyzed by flow cytometry
as follows: B cells (memory, regulatory, and mature subsets), T cells (effector and regulatory sub-
sets), and natural killer (NK) cells (CD56dim and CD56bright subsets).
Results: Our results show that teriflunomide significantly reduces absolute counts of total
CD191 B cells and mature and regulatory B-cell subsets. T cells were affected to a lesser extent,
with a trend in reduction of absolute counts for both T effector CD41 cells (Th1, Th17 and Th1/
17) and T regulatory CD81 and CD41 cells. Teriflunomide had no detectable effect on NK-cell
numbers.
Conclusions: In our small cohort, teriflunomide treatment affects mainly and significantly on B-cell
numbers, while having a milder effect on T-cell numbers. Larger cohorts are necessary to confirm
these findings and understand the effect of teriflunomide on the functionality of these cells.
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GLOSSARY
EDSS 5 Expanded Disability Status Scale; IFNg 5 interferon gamma; NK 5 natural killer; RR-MS 5 relapsing-remitting MS;
Teff 5 effector T cell; Treg 5 regulatory T cell.
The main mechanism of action of teriflunomide, a drug approved for treatment of relapsing-
remitting MS (RR-MS), relies on the inhibition of dihydroorotate dehydrogenase, which cata-
lyzes de novo biosynthesis of pyrimidines. Cells with high proliferative rates, such as activated
lymphocytes, are therefore affected by teriflunomide.1 Accordingly, treatment with terifluno-
mide decreases proliferation of T and B lymphocytes.2 Clinical trials (teriflunomide multiple
sclerosis oral and teriflunomide oral in people with relapsing multiple sclerosis)3 have shown that
teriflunomide treatment is associated with an early 15% mean decrease in leukocyte counts.
However, the effect of teriflunomide on different immune cell subpopulations has not been
properly addressed so far. Therefore, we have investigated how teriflunomide treatment affects
immune cell populations in MS.
METHODS Flow cytometry analysis. Mononuclear cells were isolated from the peripheral blood by Ficoll gradient centrifugation
(Lympholyte-H, Cedarlane), and flow cytometry analysis, using the BD LSRFortessa flow cytometer and FACSDiva 7 Software, was
performed in 4 tubes using the following conjugated antibodies (Becton Dickinson, Franklin Lakes, NJ): anti-CD3 (V500), anti-CD4
(allophycocyanin [APC]-H7), anti-CD8 (PercCP-Cy5.5), anti-CD28 (phycoerythrin [PE], anti-CD25 (PE.Cy7), anti-CD127
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(BV421), anti-CD45RA (APC), anti-CCR6 (APC), anti-CD161
(B421), anti-CCR4 (PE.Cy7), and anti-CXCR3 (PE) for effector
(Teff) and regulatory T (Treg) cells; anti-CD19 (PE.Cy7), anti-
CD38 (APC), and anti-CD24 (PE) for B cells; and anti-CD3
(V500), anti-CD16 (PerCp-Cy5.5), and anti-CD56 (BV421)
for natural killer (NK) cells.
Flow-Count Fluorospheres (Beckman Coulter, Galway,
Ireland) were used to obtain absolute cell counts.
MS patient cohort. The longitudinal, open-label, observational
study was performed on a cohort of 10 patients with RR-MS; of
these, 3 were analyzed before treatment (T0) and after 3 months
(T3), and 7 at T0 and after 12 months (T12) of treatment. The 3
patients followed for 3 months (2 men and 1 woman) had a mean
age of 43.6 6 1.5 years, a mean Expanded Disability Status Scale
(EDSS) score of 3.0 6 1.5 throughout treatment, and a mean
disease duration of 15.3 6 10.5 years. One patient had been
treated with mitoxantrone for 6 years previously. The 7 patients
followed for 12 months were all women with a mean age of 54.86
8.9 years; the mean EDSS score was 3.0 6 1.5 and 3.1 6 1.7
before and after 12 months of treatment, respectively, and a mean
disease duration of 13.46 4.8 years. One patient had been treated
with cyclophosphamide andmitoxantrone 7 years previously. Other
previous treatments included interferonb-1a, interferonb-1b,
natalizumab, and dimethyl fumarate. Patients did not experience
relapses during treatment.
Patients were enrolled according to the following criteria:
age 18 years and older, with a diagnosis of RR-MS (Poser or
McDonald criteria) and an EDSS score of 0–6.5, and able to
provide written informed consent.
Ethics approval. This study was approved by the Ethics Com-
mittee of Ospedale Policlinico San Martino—IRCCS, Genoa,
Italy, No. 190/12.
Figure 1 B cells decrease significantly in patients with MS during teriflunomide treatment
B cells are assessed as CD32CD142CD191 of which subpopulations are identified as B memory (B mem CD241CD382), B
mature (B mat CD241CD38low), and B regulatory (B reg CD241CD38high). (A) A clear trend in reduction of B-cell number and
percentage was observed in 3 patients treated for 3 months. (B) B-cell percentage (upper panel) and numbers (lower panel)
were reduced after 1 year of treatment with teriflunomide. Data are presented as mean 6 SEM for 7 treated patients with
MS. *p, 0.05. (C) While the proportions of the different B-cell subpopulations did not change after 12months of treatment
(upper panel), numbers of Bmat and B reg cells were decreased (*p, 0.05), and Bmem cell numbers showed a clear trend to
decrease (lower panel). Data are presented as mean 6 SEM for 7 treated patients with MS.
2 Neurology: Neuroimmunology & Neuroinflammation
Statistical analyses. Statistical analyses were performed
using Graph-Pad Prism v.6.00 (GraphPad Software, San
Diego, CA). Statistical significance was evaluated using
the paired Student t test (Wilcoxon matched-pairs signed-
rank test). p Values #0.05 were considered statistically
significant.
RESULTS A preliminary assessment by flow cytom-
etry of the effect of teriflunomide on broad immune
cell subsets (CD31T cells, CD191B cells, and
CD561NK cells) in 3 patients after a three-month
treatment indicated that CD191B-cell percentage
and numbers decreased in all 3 patients (figure 1A),
while no apparent effect was observed in the other cell
populations (data not shown). To further define the
effect of teriflunomide, we evaluated its effect on cell
number and proportion of relevant immune cell
subsets after a 12-month treatment in 7 different
patients. As expected, the overall lymphocyte counts
in all treated patients were slightly decreased (by
around 10%; data not shown).
B cells decrease in patients with MS during teriflunomide
treatment. A significant reduction in cell number
and percentage of B cells overall was confirmed in
patients treated for 12 months (figure 1B). While
the proportions of the different B-cell subpopula-
tions remained stable (figure 1C upper panel), B
mature and B regulatory cell numbers were signif-
icantly decreased, and B memory cells also
Figure 2 T effector and regulatory cell numbers show a slight trend in reduction after 12 months of teriflunomide treatment
Effector T-cell populations were assessed as Th1 (CD31CD41CCR62CD1612), Th17 (CD31CD41CCR61CD1611), and Th1/17
(CD31CD41CCR61CD1611CXCR3highCCR4low). Regulatory T-cell subpopulations were assessed as CD31CD41 (including Treg CD251CD1272 and Treg-
naive CD45RA1CD25low) and CD31CD81 (including Treg CD282 and Treg–naive CD282CD45RA1). (A) T effector cell numbers show a trend in decrease
after 12 months of treatment. (B) The proportion between different regulatory T-cell subsets is not affected by teriflunomide (lower panel). The number of
cells is slightly reduced in all subpopulations after 12 months of treatment (upper panel). (C) The proportion between different T effector cell subsets is not
affected by the treatment. Data are presented as mean 6 SEM for 7 treated patients with MS.
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decreased, albeit not significantly (figure 1C
lower panel).
Teriflunomide treatment slightly decreases T-cell numbers,
albeit nonsignificantly. A slight trend to reduced num-
bers was seen in Teff (figure 2A) and Treg (figure 2B
upper panel) cells after 12 months of treatment,
whereas the percentage of Teff and Treg cells did not
change (figure 2C and figure 2B, lower panel).
Teriflunomide treatment does not decrease NK-cell
numbers. Figure 3 shows that percentage and num-
bers of total NK cells remained stable after 12
months of treatment (figure 3, A and C), and there
was no difference in the proportion and absolute
counts of CD56bright and CD56dim NK cells
(Figure 3, B and D).
DISCUSSION MS is an inflammatory autoimmune
disease involving several types of immune cells with
effector and regulatory functions including T and B
lymphocytes. While autoreactive CD41 Teff cells
are believed to drive autoimmune diseases when they
escape central tolerance, several mechanisms have
evolved to regulate their function in the periphery
and prevent autoimmunity. Different Treg-cell sub-
sets have been characterized as being able to suppress
lymphocyte effector functions either directly or by
acting on antigen-presenting cells, therefore pre-
venting the development of autoimmunity. In MS,
Treg suppression has been reported to be dysfunc-
tional. The role of Th1 interferon gamma (IFNg)-
secreting cells is well known as a major protagonist in
demyelinating damage in MS4; more recently, other
Teff-cell subpopulations have been discovered to have
a major role in the inflammatory process of MS:
Th17 and Th1/17 lymphocytes secreting IFNg and/
or interleukin-17. In particular, Th1/17 cells are
increased in patients with MS compared with healthy
donors during active phases of disease.5 Our data
show that the numbers of circulating Teff and Treg
cells are slightly, albeit not significantly, decreased by
teriflunomide treatment. As teriflunomide affects
predominantly cells that are highly proliferative, this
suggests that, in our cohort of patients who did not
suffer any relapse during the period of observation,
the rate of proliferation of these cells is likely low.
B lymphocytes are emerging as key player in the
pathogenesis of MS. Three B-cell subsets have been
described: effector, regulatory, and memory cells
characterized by different roles depending on the
production of antibody and of different cytokine
types. Aberrant profiles of both types of cytokine
responses have been observed in B cells from pa-
tients with MS.6 Our study shows that terifluno-
mide significantly decreases cell numbers of effector
B-cell subsets, confirming the importance of targeting
B cells to obtain clinical and radiologic stabilization
of disease, as shown with B-cell–specific treatments
such as rituximab7 and ocrelizumab.8 The effect of
teriflunomide on mature B cells may be of clinical
importance in view of the observed recirculation of
B cells between peripheral tissues and the CNS,9
Figure 3 NK-cell subsets are not influenced by teriflunomide treatment
NK cells are assessed as CD32CD142CD56bright and CD32CD142CD56dim cells. The percentage of the overall population
(A) or the CD56bright and CD56dim subsets (B) did not change on treatment, nor did the actual cell number (C and D,
respectively). Data are presented as mean 6 SEM for 7 treated patients with MS.
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with a possible pathogenetic effect. However, teri-
flunomide also decreases the Breg-cell subset, as its effect
on lymphocytes is not specific toward a single cell pop-
ulation, but rather targets proliferating cells. It is as yet
unknown what are the roles of Breg cells in MS and the
clinical relevance of changes induced by treatments on
this cell population. However, it should be noted
that efficient specific B-cell–depleting treatments such
as rituximab and ocrelizumab, would also affect the
Breg-cell population. In this context, beyond its current
utilization as first-line therapy in MS subjects, terifluno-
mide could be also considered as maintenance treatment
after induction therapy.
Our data show that teriflunomide treatment influ-
ences immune cell subsets involved in the pathogen-
esis of MS, more specifically B cells and, to a lower
extent, T cells. However, further studies with larger
cohorts and targeting cell functionality are necessary
to clarify the basis of its efficacy in MS.
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